Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

As the global weight-loss market explodes, drugmakers are now racing to solve a less visible problem: protecting muscle mass ...

For weight loss, maridebart cafraglutide is likely to be similar to tirzepatide, but “it appears that the efficacy is more than you get with just GLP-1 [agonism] alone,” she said. It’s possible the ...

And more pharma news updates from Pharmalittle.

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Those on Wegovy alone lost 15.7% of their weight, with 71.8% coming from body fat — indicating more muscle was lost when the experimental drug wasn’t included in the regimen.